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1  | INTRODUC TION
Xenotransplantation has been approaching clinical application for 
many years. What might seem a leisurely approach to clinical ap‐
plication belies rapid and gratifying progress in identifying and 
overcoming biological barriers.1 The rapid progress in xenotrans‐
plantation however has been equaled and sometimes exceeded by 
advancing standards for entry into clinical practice (a process called 
“moving the goalposts”). Viewed from a distance, then, xenotrans‐
plantation appears to be engaged in a marathon with alternative 
medical and surgical treatments, including allotransplantation, all 
potentially slowed by regulatory hurdles. The course of this mara‐
thon is eloquently brought into focus by David Cooper et al,2 who 
discuss the prospects for applying neonatal tolerance to advance 
xenotransplantation as a treatment for congenital structural heart 
disease and cardiomyopathies.
Cooper et al2 assert, no doubt correctly, that porcine hearts (and 
presumably other organs and tissues) would be acceptable alterna‐
tives to scarce human hearts as sources of transplants if tolerance to 
the source of the transplants could be safely and effectively achieved. 
Implicit in the proposition is an assumption, we think warranted, that 
concerns about transmission and/or generation of novel infectious 
agents have been overblown. The authors base their proposition on 
the observation that tolerance to blood group antigens A or B of 
the donor occurs in the preponderance ABO‐incompatible cardiac 
transplants in the newborn (eg, based on negative ELISPOT for blood 
group‐specific B cells, tolerance developed spontaneously in each of 
13 newborn recipients of ABO‐incompatible cardiac transplants3). 
The proposition could draw further support from observations that 
a small fraction (perhaps 5%) of mature recipients of kidney or liver 
allografts develop "operational tolerance" to donor HLA,4 that is, 
the grafts in mature recipients survive and continue to function de‐
spite discontinuation of immunosuppression. Further, as the authors 
note, tolerance to has been deliberately induced in small numbers of 
mature kidney allograft recipients.5,6 Cooper and colleagues would 
thus employ a hybrid approach—both the spontaneous tolerance of 
the newborn and deliberate induction of tolerance—to support the 
transplantation of porcine hearts in newborn afflicted with severe 
cardiac failure or cardiac malformations not amenable to surgical 
palliation.
The proposal takes as one assumption that spontaneous toler‐
ance and induced tolerance are not mutually inimical. We accept that 
premise for the present, although we have observed non‐pathogenic 
autoimmunity in subjects who underwent cardiac transplantation in 
infancy.7 The proposal seems to take as a related assumption that a 
newborn (or a fetus) is more accepting of foreign antigens and poten‐
tially of transplants than an adult and potentially more amenable to 
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Abstract
The newborn infant with severe cardiac failure owed to congenital structural heart 
disease or cardiomyopathy poses a daunting therapeutic challenge. The ideal solu‐
tion for both might be cardiac transplantation if availability of hearts was not limiting 
and if tolerance could be induced, obviating toxicity of immunosuppressive therapy. 
If one could safely and effectively exploit neonatal tolerance for successful xenotrans‐
plantation of the heart, the challenge of severe cardiac failure in the newborn infant 
might be met. We discuss the need, the potential for applying neonatal tolerance in 
the setting of xenotransplantation and the possibility that other approaches to this 
problem might emerge.
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observation8,9 (although not beyond dispute 10). The authors believe 
these assumptions together with the dramatic progress in extending 
the survival of xenografts beyond a year 11‐13 make newborn patients 
with severe cardiac failure ideal subjects in whom to test induction 
and sustained maintenance of xenogeneic tolerance and therefore 
ideal recipients for cardiac xenografts. After all, the authors point 
out, xenogeneic tolerance would spare the recipient (and the in‐
surance company or government) a lifetime of immunosuppressive 
therapy and if the xenograft failed (as do some allografts) the recip‐
ient might be rescued by a human allograft. We certainly agree that 
safe and effective induction of xenogeneic tolerance would have 
many benefits for the recipient, but we are skeptical about whether 
and how easily tolerance to antigens other than saccharides can be 
achieved, even in the newborn.
Implicit in Cooper's proposal is one further assumption—that 
staged reconstruction of the hypoplastic left heart and other “sin‐
gle ventricle” malformations, as effective as it might be, is not the 
ideal solution. We agree. Nearly half of those who survive the 
Fontan procedure nonetheless die or require transplantation within 
six years14,15 and transplantation after failed reconstruction has a 
greater risk of failure than a primary transplant.16 We think that car‐
diac transplantation, when available, provides a better therapeutic 
option and the only possibility of normal physiology. But, allogeneic 
cardiac transplantation, as currently practiced, is far from ideal if one 
compares the overall health of transplant recipients (ie, incidence 
of infection, malignancy, drug toxicity, chronic vasculopathy, growth 
failure, etc) to the health of infants and children of the same age. If 
allogeneic tolerance could be safely and reliably induced in the new‐
born, allowing immunosuppressive therapy to be withdrawn, the 
overall health of transplant recipients might approach that of nor‐
mal individuals and allotransplantation would then provide the ideal 
solution. In that setting, we might view a porcine cardiac transplant 
as a welcome bridge to the ideal human cardiac allograft. Further, if 
xenogeneic tolerance could be safely and reliably induced we might 
be persuaded that xenografts, which can be planned, potentially 
from the moment of birth or even before, might well be preferred 
over allografts, the function of which is less than certain. But, we 
know of no evidence that allogeneic tolerance can be safely and re‐
liably induced in adults or in newborn humans, aside from tolerance 
to blood group antigens.
The measures now used to attempt induction of tolerance in 
mature individuals—removal of the thymus and possibly thymus xe‐
notransplantation,17‐19 blockade of co‐stimulation and immunosup‐
pression regimens and modifications of pigs—extend the survival of 
some experimental xenografts in non‐human primates from months 
to beyond a year,20,21 but do not induce tolerance. Indeed, despite 
decades of work and much progress toward the goal, a safe and ef‐
fective approach to induction of tolerance in non‐human primates 
toward porcine organs or tissues has not been devised.22 However, 
Cooper et al reason that existing measures might be successful if 
applied in newborn individuals with less experienced, more forgiving 
immune systems. We agree. And, we would add that the function 
of allogeneic or xenogeneic hearts implanted in tolerant recipients 
might well be better than the function of hearts transplanted in re‐
cipients treated with immunosuppressive agents (that potentially 
compromise function of kidneys or liver if not the heart). But, we 
would also add that the more pertinent question is whether over‐
all health would be improved by measures that would decimate the 
immune system at birth and rebuild it using xenogeneic epithelial 
cells to select a T‐cell repertoire that must thereafter protect against 
microorganisms and toxins presented by self‐MHC. We are skeptical 
on that point and we consider it highly unlikely that a rigorous an‐
swer will emerge from the limited number of xenografts performed 
in newborn non‐human primates. That is why we agree when Cooper 
et al state that presently they would not undertake clinical cardiac 
xenografts in newborn infants today, recognizing that such agree‐
ment favors other non‐transplant approaches in the race to conquer 
congenital heart disease and cardiomyopathies of the newborn.
2  | SOME APPROACHES TO THE "CURE" 
OF C ARDIAC FAILURE IN THE NE WBORN
The surgical approaches presently available to infants born with se‐
vere cardiac disease are far from ideal. The hypoplastic left heart 
syndrome is relatively common and is generally treated by staged 
palliation and reconstruction, as first described by Norwood in 
198023 and as one of us (REC) reviewed.16 Reconstructive proce‐
dures continue to evolve and newer approaches are debated today.14 
However, despite these improvements, physiology is never fully re‐
stored and palliation ultimately fails in ~35%.15 When failure occurs, 
the patient must undergo cardiac allotransplantation but in this set‐
ting transplantation poses a significantly greater risk24,25 because 
the recipients are less healthy and often sensitized and the anatomy 
is compromised.16 While transplantation might be preferred as a 
primary treatment,16,26 newborn patients with univentricular hearts 
are generally not offered transplantation and the few hearts of suit‐
able size are directed to infants with conditions such as congenital 
cardiomyopathy which cannot be treated by reconstruction.
When transplantation is performed as a primary treatment, the 
outcomes are often quite good. Hearts transplanted in newborn 
recipients grow with the infant and unlike palliative surgery can 
provide normal physiology. Although rejection can compromise the 
function and survival of cardiac transplants in newborn recipients, 
chronic rejection is notably less prevalent than in hearts trans‐
planted in older children and adults.16,27 The recipients of cardiac 
transplants must of course take immunosuppressive drugs for life 
and hence suffer heightened age‐adjusted risk of infection and ma‐
lignancy,28 but these risks are also experienced by the ~35% of those 
who undergo palliative surgery and then require transplantation for 
rescue. Still, because suitable donors are scarce, less than 100 car‐
diac transplants in newborn infants can be performed annually in the 
United States and ~25%‐35% of newborns awaiting transplantation 
die before a heart becomes available.29,30 Accordingly, Cooper and 
colleagues join others31,32 who propose that xenotransplantation 
could potentially address this agonizing challenge and further advise 
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that advances in the genetic engineering of pigs and the relative ease 
of inducing tolerance in the newborn (aided by removal of thymus 
in conjunction with cardiac surgery) might bring the solution much 
closer potentially even averting need for ongoing immunosuppres‐
sion. Whether one agrees or disagrees with Çooper's proposition, 
much can be learned by considering several of the details.
3  | GR AF T ACCEPTANCE E ARLY IN LIFE
For more than a century, experimental biologists have observed that 
fetuses and newborn individuals can in some circumstances accept 
grafts of normal or malignant tissues from other individuals that 
mature animals do not.8 Acceptance of foreign cells by a fetus may 
reflect immune incompetence rather than tolerance but the pres‐
ence of foreign cells from early in life can spontaneously induce tol‐
erance. Indeed, the observations that dizygotic twins of cattle can 
have spontaneous hematopoietic chimerism33 and that each of a 
pair of cattle twins, whether dizygotic or monozygotic, would accept 
grafts of skin from the other twin but not from unrelated cattle34 led 
to the concept of immunological tolerance. The observations also 
led to the idea that one might deliberately introduce foreign cells in 
a fetus or newborn to generate a condition in which the recipient of 
the foreign cells would later accept a graft from the source of the 
foreign cells 35(see 36,37 for review).
Fetuses and newborn individuals also can in some circumstances 
spontaneously accept grafts from xenogeneic sources.8 Fetal sheep, 
dogs, and pigs can accept human hematopoietic cells and the cells 
can be found at various levels months or years after birth.38‐40 
Whether the introduction of xenogeneic (human) cells in fetal pigs 
generates robust xenogeneic tolerance is not clear, but it can induce 
source‐specific immune non‐responsiveness that persists long after 
birth (eg, human hematopoietic stem cells administered to a pig fetus 
induces non‐responsiveness to APC of the stem cell donor with no 
loss of responsiveness to third‐party APC in pigs tested a year after 
birth).41
In contrast to seminal observations in the mouse, foreign tissues 
or organs transplanted into newborn non‐human primates are re‐
jected unless immunosuppression is administered and spontaneous 
tolerance to foreign tissues does not occur. Rob Michler trans‐
planted hearts from newborn pigs heterotopically into 5 newborn 
baboons that were untreated and 5 treated with a "clinically‐rele‐
vant" regimen of immunosuppression.42‐44 The xenografts in un‐
treated recipients were rejected at a mean of ~3 days, and grafts in 
immunosuppressed recipients were rejected at a mean of ~6 days. 
This experience, albeit limited, suggests Cooper and colleagues are 
correct to assume a human newborn infant would not spontaneously 
accept a cardiac xenograft.
3.1 | A suggestion
Although newborn individuals do not spontaneously accept al‐
lografts or xenografts, mammalian fetuses may do so. If a cardiac 
anomaly is detected in utero, one might introduce allogeneic or xeno‐
geneic stem cells or xenogeneic progenitor cells with the hope that 
they might be spontaneously accepted and later used to repair the 
defect or improve function. Acceptance of foreign cells delivered to 
the fetus however does not necessarily impart tolerance.45
4  | NEONATAL TOLER ANCE IN 
TR ANSPL ANTATION
Human newborn infants do spontaneously develop tolerance to the 
allogeneic blood group antigens expressed in ABO‐incompatible car‐
diac transplants.3,46 The governance of B‐cell responses and toler‐
ance to saccharides is incompletely understood. Antibodies specific 
for some saccharide antigens, such as blood groups A and B and 
Galα1‐3 Gal, are usually absent at birth 2,3,42,46‐48 but after months 
or years appear spontaneously in all immune‐competent individu‐
als who lack the corresponding antigen.49 Foreign saccharide anti‐
gens or cells expressing those antigens do not elicit anti‐saccharide 
antibodies in newborn infants, and therefore, organs bearing those 
antigens are not subject to hyperacute or acute antibody‐mediated 
rejection .47,50 Whether absence of these antibodies in the newborn 
reflects tolerance, that is, antigen‐specific non‐responsiveness or 
a general inability to respond to saccharide antigens is not known. 
Therefore, the initial acceptance of an organ across a blood group 
barrier (including Galα1‐3 Gal) cannot be taken to reflect tolerance. 
Months or years later, however, the recipient of an ABO‐incompat‐
ible heart transplant produces antibodies against blood group an‐
tigens not present in the graft or in their own blood and then, the 
absence of a B‐cell response to antigens in the graft and demon‐
strable response to allogeneic saccharides fulfills the definition of 
tolerance.3,46 Since B cells specific for saccharide antigens turnover 
continuously, absence of a response to saccharides in the graft in‐
dicates that tolerance reflects an ongoing process. Why older re‐
cipients of ABO‐incompatible grafts do not also experience this 
ongoing process and develop tolerance to the foreign saccharides 
in their grafts is unclear.51 Various testable explanations might be 
proposed.52,53
Whether or not tolerance to foreign saccharides develops, non‐
saccharide antigens pose the greater challenge in transplantation. 
Indeed, it was this challenge that identified histocompatibility anti‐
gens and the dramatic experiments overcoming that challenge that 
identified tolerance.36 Still, when one considers applications of neo‐
natal tolerance, it is wise to recall that the original work on induced 
tolerance in allotransplantation revealed that only ~10% of new‐
born mice given a mixture of cells from an allogeneic strain would 
later accept skin grafts from the same allogeneic strain of mice.35,54 
Subsequent work by others 55 and by one of us (LJW) 56,57 success‐
fully induced allogeneic tolerance in nearly all mice of some strains 
but failed to induce tolerance in mice of other strains, the genetic 
background, H‐2 and certain minor antigen incompatibilities being 
key determinants. What factors would govern tolerance and graft 
acceptance in human newborns is unknown.
4 of 9  |     PLATT eT AL.
Because tolerance to non‐saccharide antigens, for example, 
MHC‐encoded antigens and minor antigens, expressed by foreign 
tissues does not develop spontaneously after transplantation in the 
newborn period, newborn recipients of cardiac transplants always 
receive immunosuppression. Therefore, Cooper and colleagues 
are wise not to rely on spontaneous newborn tolerance to sustain 
cardiac xenografts in newborn recipients. Instead, they propose 
measures such as thymus xenotransplantation and blockade of co‐
stimulation that are being pursued for induction of xenogeneic toler‐
ance in mature individuals,19,22,58 reasoning, the measures would be 
more effective in newborns than in adults.
4.1 | A suggestion
Characteristics that make the immune system of the newborn more 
amendable to induction of tolerance and more forgiving of a trans‐
plant make the newborn more susceptible to infection. Given the 
daunting barriers to induction of xenogeneic tolerance in mature 
individuals,22 toxicity rather than efficacy in early infancy will likely 
prove limiting. Therefore, where possible, we would pursue toler‐
ance by introduction of foreign cells in the fetus, since doing so pre‐
serves host defense.
5  | THE SOURCE OF HE ARTS FOR 
C ARDIAC XENOGR AF TS IN NE WBORN 
INFANTS
As sources of hearts for transplantation in newborn infants, Cooper 
and colleagues propose using pigs with various genetic manipula‐
tions, but especially pigs with targeted disruption of enzymes that 
synthesize three saccharides recognized by human natural antibod‐
ies. Long‐term survival achieved using hearts from pigs lacking one 
or more of these saccharides, including "triple KO pigs" proposed for 
use, has generated much excitement, seemingly bringing xenotrans‐
plantation to the verge of clinical application (see 59 for review). Still, 
some might wonder why in an approach to induction of tolerance in 
neonates would omit the only types of substances proven to induce 
tolerance in human neonates.3 Notwithstanding this contradiction, 
we think there is an interesting and potentially fertile logic to the 
proposal.
Although loss of tolerance to autologous‐blood group A or B 
saccharides has never been described and newborn recipients of 
ABO‐incompatible cardiac transplants exhibit enduring tolerance 
to blood groups of the donor,60‐62 there is as yet no proof that the 
tolerance that develops to allogeneic saccharides in recipients of 
cardiac transplants is as robust as tolerance to self. Indeed, some 
recipients of ABO‐incompatible cardiac transplants performed 
after the newborn period have low concentrations of antibodies 
that bind to donor‐type erythrocytes.51 Work by one of us (LJW) 
indicates at least some of these antibodies recognize determinants 
not present in the graft and hence are not subject to the processes 
that engender tolerance.61 On the other hand, as we discuss in 
detail elsewhere ,53,63,64 absence of antibodies in serum against 
donor antigens, particularly blood group antigens cannot be taken 
as proof of tolerance because organ transplants can absorb enor‐
mous amount of antibody when accommodation is present .53,63
Why is tolerance to foreign saccharides readily induced in infants 
but not in older individuals? The principle mechanism usually consid‐
ered is that immaturity of B cells in newborn infants favors devel‐
opment of tolerance over immunity when the cells confront foreign 
saccharides (analogous to development of tolerance rather than im‐
munity when newborn mice confront by foreign histocompatibility 
antigens). While appealing, this explanation does not explain how 
tolerance to blood groups is maintained as new B cells are produced 
in mature individuals. Nor can a developmental mechanism alone ex‐
plain anecdotal reports of development of anti‐recipient isohemag‐
glutinins in cord blood transplantation or the transient appearance 
and then loss of isohemagglutinins in peripheral stem cell transplant 
recipients.65 Thus, factors extrinsic to B cells probably contribute to 
the maintenance of B‐cell tolerance and offer possibilities for thera‐
peutic applications in xenotransplantation.
One factor that could explain the development of tolerance in 
newborn and responsiveness in older recipients of ABO‐incompati‐
ble cardiac transplants concerns age‐ or treatment‐related changes 
in gut mucosa or in gut microorganisms. Cells of mature intestinal 
mucosa produce plentiful mucin proteins with polysaccharide sub‐
stitutions, including blood group antigens and mucin‐derived poly‐
saccharides have been used as immunogens to generate polyclonal 
anti‐blood group antibodies. Gut bacteria can produce saccharides 
that cross‐react with blood group antigens and these bacterial sac‐
charides have been implicated as the primary stimulus for natural 
production of isohemagglutinins.66 In principle, either source of an‐
tigen could suffice to generate immunity to blood group antigens. 
However, endogenous cells outside of the gut might release blood 
group saccharides in sufficient amounts (perhaps as monomer) to in‐
duce tolerance and/or compete with polymerized saccharides when 
antigen‐specific B cells begin slowly to be produced. An ABO‐incom‐
patible cardiac transplant might also release enough saccharide like‐
wise to induce tolerance. On the other hand, the existing repertoire 
of B cells specific for blood group antigens would probably require a 
much larger amount of saccharide to induce tolerance or to compete 
with cross‐reactive bacterial polysaccharides and this amount prob‐
ably exceeds the small amounts emitted from the graft.
Another factor concerns the differential impact of polymerized 
and monomeric antigen on B cells. Polymerized antigen that cross‐
links B‐cell receptors can induce B‐cell responses without T cell‐help 
(ie, they are T‐cell independent).67,68 Membrane fragments released 
from the transplant at the time of surgery might stimulate B cells 
remote from the transplant (and hence not be subject to inhibition 
by small amounts of monomeric saccharides continuously released). 
Since the newborn infant has few if any B cells capable of respond‐
ing, the transplant procedure and early episodes of rejection do not 
generate B cells responses and as B cells are later produced they are 
subject to control by ongoing release of endogenous saccharides. On 
the other hand, in more mature recipients, polymerize saccharide or 
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membrane fragments released from the graft at the time of reper‐
fusion or during rejection trigger responses of existing B cells. We 
have postulated this mechanism might explain the evolution of B‐cell 
responses in tissue grafts and contribute to accommodation in organ 
grafts.52,53
A third factor that could explain development of tolerance in 
newborn but not in older recipients of ABO‐incompatible cardiac 
transplants concerns the differences in the durability of delivery 
of tolerizing antigen to B cells. Persistence of tolerance depends on 
delivery of antigen in some form to bone marrow and spleen where 
B cells that generate T cell–independent B‐cell responses mainly 
reside. Although donor blood group antigens persist for years in 
cardiac transplants,3 whether the amount or form of this antigen 
reaching bone marrow and spleen suffices to maintain tolerance is 
uncertain; whether the amount and form of xenogeneic antigen that 
would reach B cells of recipients is likewise unknown. In ABO‐in‐
compatible transplantation, passenger leukocytes provide a poten‐
tial source of tolerizing antigen and the persistence and renewal of 
passenger leukocytes from newborn hearts (instead of or in addition 
to B‐cell immaturity) might explain the persistence of tolerance after 
removal of an ABO‐incompatible organ transplant.69 The limited ca‐
pacity for renewal of passenger leukocytes associated with mature 
organs might explain absence or loss of tolerance in older recipients 
(who do not receive organs from newborn donors). Cooper and col‐
leagues might find that organs from newborn pigs are more apt to 
induce tolerance than organs from mature pigs.
5.1 | A suggestion
Various factors discussed above might be exploited to limit immunity 
and perhaps promote development of tolerance in xenograft recipi‐
ents. Manipulation or engineering of gut bacteria, delivery of antigen 
in tolerogenic form and/or expression of antigen in stem cells, possi‐
bly of recipient origin, might help limit immunogenicity of xenografts 
or facilitate tolerance without imposing risk on vulnerable infants.
6  | POTENTIAL "TOXICIT Y " OF 
XENOTR ANSPL ANTATION
The potential risks of xenotransplantation, such as the conveying 
of microbial agents, have been discussed elsewhere and require no 
further mention here. Concerns about infection that once seem‐
ingly blocked clinical application of xenotransplantation are much 
abated.12 However, certain risks unique to xenotransplantation in 
newborn recipients merit consideration.
The most obvious risk stems from immunosuppressive regimens 
or approaches to induction of tolerance that limit the ability of a re‐
cipient to mount a primary immune response to the microorganisms 
infants commonly confront. Those who undergo cardiac transplan‐
tation in infancy, and hence removal of the thymus, T‐cell depletion 
and maintenance immunosuppression have marked contraction of 
the T‐cell receptor repertoire and higher levels of human herpesvirus 
replication than normal individual but suffer no obvious conse‐
quences.7 One must be concerned that further measures, such as 
co‐stimulation blockade, might allow these or other common viruses 
to disseminate or engender pathology. Although thymus transplan‐
tation, potentially can correct the defect, as Cooper and colleagues 
mention, survival of thymus transplant recipients (who do not re‐
ceive immunosuppression), is no better than survival of infants with 
severe univentricular anomalies.70
A more interesting problem is potentially generated by genetic 
engineering of pigs to eliminate saccharides targeted by the natu‐
ral antibodies present in mature humans but absent in newborns. 
Among other functions, saccharide substitutions potentially block 
the targets of elicited immune responses. Some human proteins 
with truncated modifications elicit powerful T cell–dependent B‐cell 
responses and foreign cells expressing modified proteins and lip‐
ids are often less immunogenic. This possibility has implication for 
transplantation as newborn recipients of ABO‐incompatible cardiac 
transplants develop less robust responses to allogeneic HLA than 
recipients of ABO‐compatible cardiac transplants.60 It would ironic 
to the extreme if understandable zeal to eliminate antigens from or‐
gans designed for transplantation inadvertently prevented develop‐
ment of tolerance and increased the need for immunosuppression in 
newborn recipients of cardiac xenografts.
Another concern, still merely theoretical, is whether any of the 
genetic modifications undertaken to decrease antigen expression, 
inflammation, coagulation etc confer risks in the newborn that would 
be difficult to appreciate in mature individuals. As elsewhere de‐
tailed,71 binding of natural antibodies, activation of complement and 
initiation of coagulation and thrombosis at a local level prevent colo‐
nization and dissemination of microorganisms. Local containment of 
microorganisms and removal from endocardium are probably much 
more important in immunologically naive newborn infants than in 
mature individuals.
6.1 | Some suggestions
While Cooper and colleagues wait until the time is ripe to transplant 
hearts from "triple‐knockout pigs" into newborn infants, we might 
suggest they assure the sources of xenografts and treatment regi‐
mens are safe and optimized for the newborn infants. We would 
compare the immunogenicity of proteins and organs from "triple‐
knockout pigs" with immunogenicity of organs from pigs expressing 
those saccharides in newborn animals treated with proposed regi‐
mens of immunosuppression; not with respect to binding of natural 
antibodies but as triggers of elicited immune responses. We would 
compare the baseline and adaptive functions and the durability of 
"triple‐knockout" hearts with those of wild‐type hearts. How one 
might persuade "triple‐knockout" pigs to use a treadmill is beyond 
our imagination, but some functions can be discerned by echo‐ and 
stress‐echocardiography. We would test the function and durabil‐
ity of triple‐knockout hearts transplanted in newborn wild‐type 
pigs, immunosuppressed as Cooper and colleagues have suggested, 
to make sure these are not limiting. Aside from the proteins with 
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saccharide substitutions, we suspect the hearts of triple negative or 
αGal‐deficient pigs are no more immunogenic or susceptible to in‐
jury than wild‐type hearts but why not confirm those suspicions (eg, 
by testing kinetics of rejection of male‐to‐female grafts and/or re‐
covery from coronary occlusion). While Cooper and colleagues wait 
to use these hearts, we hope someone will make sure the hearts are 
worth the wait.
7  | POTENTIAL COSTS OF DEL AYING 
CLINIC AL APPLIC ATION OF 
XENOTR ANSPL ANTATION
On the other hand, there are reasons to resist the temptation 
to delay clinical application (if not this particular application) of 
xenotransplantation. As we discuss elsewhere,59 pig‐to‐non‐
human primate models may well have reached the limits for pre‐
dicting the outcome of clinical applications. Put in another way, 
porcine organs transplanted in humans today might well survive 
longer and function better than the same organs transplanted in 
non‐human primates. The diagnostic and therapeutic resources 
(and dollars) that support clinical transplants eclipse by far the 
resources that support experimental transplants, allowing earlier, 
more precise and more effective interventions if clinical xeno‐
grafts were to fail or complications were to arise. Further, immu‐
nity generated by xenogeneic organ grafts in non‐human primates 
might also target human products of transgenes intended to over‐
come incompatibilities of control of complement and coagulation, 
etc Therefore, some genetic engineering of pigs that improves the 
outcome of experimental xenografts in non‐human primates might 
have no benefit in clinical xenografts.
But, what we think could have the greatest impact on the out‐
come and application of xenotransplantation is not the development 
of new strategies for immunosuppression or iterations of genetic 
modification but experience. Given the extraordinary successes of 
recent years in prolonging the survival of organ xenografts in non‐
human primates,13,21,72,73 we think the emphasis should be given 
to identifying the best clinical setting(s) for early application of xe‐
notransplantation. For reasons we shall explain in closing, we think 
those settings might not include permanent xenografts in newborn 
infants with severe cardiac failure, but eventually could very well 
include bridge transplants.
8  | THE BENEFIT OF E XPERIENCE
Some important lessons are potentially drawn from reflecting on 
what might have been the most famous clinical xenograft. The xeno‐
graft was performed at Loma Linda University in 1984 in a newborn 
infant with hypoplastic left heart syndrome, commonly referred to 
as Baby Fae.74 The xenograft was performed because surgical pal‐
liation was unacceptable, a newborn human heart was not available 
(and had never been transplanted successfully) and death of the 
patient appeared imminent. Further, there was much experience in 
experimental transplants of baboon hearts.75
The cardiac xenograft in Baby Fae functioned reasonably well for 
more than two weeks (it was the longest surviving heart transplant, 
allo‐ or xeno‐, in a newborn recipient at that time). However, myo‐
cardial function deteriorated, the concentration of cardiac enzymes 
in blood increased, a biopsy revealed myocardial injury and renal 
failure ensued after the second post‐operative week and progressed 
leading to death at three weeks. The cause(s) of graft failure and 
Baby Fae's demise remains a matter of speculation. Much attention 
has focused on ABO‐incompatibility between the baboon (nearly all 
are blood type A or B or AB) and Baby Fae, who was blood group 
O.74 However, there are reasons to question the significance of this 
disparity. First, the histopathology conveyed in original reports sug‐
gests prominent vascular damage but immunopathology revealed 
only sparse deposits of Ig and complement and endothelium of large 
blood vessels, particularly donor aorta, was unremarkable.74 Second, 
experience discussed above suggests that blood group incompatibil‐
ity of a heart transplant is not likely to cause dysfunction of a heart 
transplant in a newborn transplant recipient.46,47 On the other hand, 
the recipient received blood products that might well have con‐
tained isohemagglutinins and these passively transferred antibodies 
could have contributed to graft injury. However, the delay in onset 
of dysfunction and injury to >14 days after transplantation would 
seem more consistent with the kinetics of dysfunction and rejection 
observed in concordant cardiac xenografts than with injury caused 
by natural immunity or passive transfer of antibodies. Further, the 
outcome of the transplant in Baby Fae might well have been the best 
outcome that could have been achieved for any cardiac transplant, 
allograft or xenograft, in a newborn recipient at that time and it is 
likely that long‐term survival and function would have been ob‐
served with the immunosuppression regimens and medical support 
presently used (20 years ago at Loma Linda most concordant xeno‐
grafts in mature recipients given clinical immunosuppression regi‐
mens survived >1 year).76 However, none of the saccharide antigens 
thought to impair transplantation of hearts from pigs into humans 
should have been pertinent to the fate of the transplant in Baby 
Fae. It is nonetheless possible that function and/or recovery from 
rejection were hindered by yet unknown incompatibilities between 
baboon and human. That possibility should make us pause before 
we assume the outcomes of "humanized" pig organs transplanted 
into baboons faithfully represent the outcome to be expected if the 
organs were transplanted into human recipients.59
9  | TOWARD A SOLUTION FOR C ARDIAC 
FAILURE IN THE NE WBORN
In closing, we must consider whether in the end an unlimited sup‐
ply of organs from optimally engineered pigs and the potential 
for inducing tolerance will eventually make cardiac xenotrans‐
plantation the ultimate treatment of severe cardiac failure of the 
newborn. Despite our enthusiasm about achievements to date in 
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xenotransplantation and a quickening rate of progress, we wonder 
whether other technologies will surpass xenotransplantation as 
solutions to the problem.
Some think implantable biocompatible devices of suitable 
size drawn from the shelves of centers that treat cardiac failure 
in infancy will eventually gain the forefront. We find it difficult 
to imagine how a device implanted in a newborn could adapt as 
well as a transplant to variations in activity and to growth, but we 
are not engineers. Others think a bioengineered heart generated 
by ex vivo perfusion of various types of stem cells from a patient 
through a matrix (perhaps a de‐cellularized pig heart) will provide 
an implantable autologous organ.77,78 If it functioned and adapted 
and endured like a normal heart, it would be difficult to fault this 
alternative, except from the perspective of cost, which would be 
high.
An approach we would favor, at least from the perspective of 
cost, is the possibility that an autologous heart might be generated 
by "in vivo organogenesis" using stem cells harvested from or gener‐
ated by reprogramming mature cells from the patient.79‐83 For some 
applications, organogenesis might be induced in the patient, but a 
more conducive environment and safer approach for generation of 
a heart could be a reverse xenograft in which pluripotent or partly 
induced human stem cells are introduced into a fetal animal, such 
as a pig.59 After organogenesis has begun, the primordial organ or 
induced cells can be transferred back to the patient in whom forma‐
tion of the organ and vascularization are completed. If still remote, 
the concept has attracted increasing interest and enjoyed some 
progress.
Successful application of bioengineering or organogenesis for 
the treatment of cardiac failure in the newborn infant or in older 
individuals depends on having a safe and reliable way to support 
cardiac function during the period of months needed for the au‐
tologous organ to form. One approach could be performance of a 
bridge xenograft eventually to be replaced by the autologous organ. 
Cooper's proposal makes the application of bridge xenografts easier 
to imagine.
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